Mark W Hahn
CIK 1408502 · Chief Financial Officer · last filed 2026-05-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
4
Total Filings
66
Lifetime Open-Market Net
-$35.05M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SOLENO THERAPEUTICS INC (SLNO) Delisted | Director | 0 | $53.01 | $0 | $0 | 2 | 2026-05-18 |
| Verona Pharma plc (VRNA) Delisted | Chief Financial Officer | 3,285,280 | $106.91 | $351.23M | -$35.03M | 42 | 2025-10-08 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | Chief Financial Officer | 0 | — | — | -$27.9K | 7 | 2019-11-12 |
| MELINTA THERAPEUTICS, INC. /NEW/ (CEMP) Delisted | EVP and CFO | — | — | — | $0 | 7 | 2017-02-27 |
Recent Filings · Page 4 of 7
66 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-03 | Verona Pharma plc (VRNA) Delisted | Tax (F) | −88,544 | -$171.0K | EDGAR |
| 2024-02-05 | Verona Pharma plc (VRNA) Delisted | Tax (F) | −480,664 | -$1.10M | EDGAR |
| 2023-11-03 | Verona Pharma plc (VRNA) Delisted | Tax (F) | −809,008 | -$1.41M | EDGAR |
| 2023-10-24 | Verona Pharma plc (VRNA) Delisted | Grant (A) | +800,000 | $0 | EDGAR |
| 2023-08-07 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −275,888 | -$693.9K | EDGAR |
| 2023-08-03 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −179,648 | -$474.9K | EDGAR |
| 2023-05-03 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −455,528 | -$1.17M | EDGAR |
| 2023-02-03 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −413,168 | -$1.06M | EDGAR |
| 2022-12-21 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −600,000 | -$1.27M | EDGAR |
| 2022-11-03 | Verona Pharma plc (VRNA) Delisted | Mixed | −468,016 | -$749.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.